CSA Medical, a Boston, Ma-based developer of The RejuvenAir System, a medical device advancing liquid nitrogen spray cryotherapy for the treatment of chronic bronchitis, raised $53M in Series D funding.
The round was co-led by TVM Capital Life Science and Yonjin Venture, with participation from SV Health Investors, Ascension Ventures, First Analysis, Blue Heron, and Intersouth Partners. In conjunction with the financing, Dr. Luc Marengere of TVM and Dr. Deng Mao of Yonjin Ventures will join CSA Medical’s Board of Directors.
The company intends to use the funds to finance its launch in the United States, despite the anticipated premarket approval (PMA) from the U.S. Food and Drug Association (FDA) and the development of a comprehensive commercialization strategy.
Led by CEO Wendelin Maners, CSA Medical is committed to developing spray cryotherapy devices that improve the lives of people suffering from COPD with Chronic Bronchitis. It is empowering its core liquid nitrogen spray technology, RejuvenAir, to target the underlying cause of chronic bronchitis – the over production of mucus and damaged cilia within the airways. By targeting and destroying these damaged cells without creating scar tissue, the body can begin the rapid regrowth of new, healthy normal functioning cells in the lung.
Commenting on the news, Wendelin Maners said: “This new investment further validates the enormous market potential for the RejuvenAir therapeutic platform in this under-served patient population.”
